Andrew Brack

What if we had therapies to extend healthspan and prevent the onset of age related diseases? I’m excited to announce my first @ARPA_H program, PROSPR. The goal is to develop validated surrogate biomarkers, new clinical endpoints and therapies to collectively extend healthspan by 20 years for all Americans.

@celinehalioua Amplifying

loyal on 60 minutes this weekend!

@AndyKilianski This is the gift that keeps on giving

Thrilled to see the broad participation in the OpenADMET challenges! Come be a part of history!!

A medicine is only helpful if you take it. The benefits of exercise and healthy living are clear. The reality is that far too few people do it. As someone who wants to maximize healthy lifespan for every person we need additional solutions.

The boxer my father named me after, Alexis Arguello, was the world's first 3-weight world champion before facing an opponent who cheated. Boxing is only great when it's fair, and @jabbr.ai is here to make it so!

@ArtirKel And will inform each other

Various ways to think about aging, roughly in order of when they became popular: 1. Longevity 1.0: Target the well conserved pathways (mtor, foxo3, ampk etc) and their regulators. 2. Longevity 2.0 The SENS/Hallmarks view: Remove damage, typically concrete molecular entities or cells, as well as adding back what was lost (like stem cells) 3. Longevity 3.0: Organisms can mostly fix their aging if they tried, they just 'forgot' how to or are "stuck" in some way (information loss (Sinclair), loss of morphostasis (Levin)) so what's needed is to nudge them in the right direction (e.g. reprogramming) and they can sort the rest out. None of these are "true" or "false", they are all incomplete, but I think of them as useful.

@KarlPfleger I was poking fun based on your claim that you had a more accurate measure. I’m good on wherever your analysis places me.

@BrackLab Sorry to disappoint but it's alphabetical within the large coarse overall scores. So you are one of N people with a score of X whose last name happens to start with B. The ranking is not meant to be a good one. Just to separate out people into generally high vs mid vs low.

YES!!!! I’m 148th on the objective measures longevity list. Hopefully I’ll break top 100 next year😂

@RapaNews This points to the selection criteria of why these compounds were tested-when resources are limited. Personally, I’m not surprised at all. Who advocated for these?

New March 2026 ITP results - Its All Bad News rapamycin.news/t/new-march-20…

A very important point is the safety point: this paper shows you can significantly decrease myostatin levels throughout a person’s lifetime, and the result is more muscle, less fat, increased strength, and no noticeable side effects

The search for ARIA’s next cohort of Programme Directors has begun 🚀 As an ARIA PD, you will design and actively manage a ~£50M R&D programme within or around our opportunity spaces with the goal of unlocking scientific and technological breakthroughs that benefit everyone. There is no one way to be an ARIA PD – our existing cohorts come from a range of backgrounds, including academia, entrepreneurship, invention and industry, and have launched programmes in areas ranging from synthetic plants to multi-agent coordination to brain surgery-free neurotechnologies. Full applications will open in August 2026 for a May 2027 start date – over the coming months we’ll be running webinars and in-person events across the UK, Europe, the US and Asia where you’ll get the chance to engage directly with the ARIA team and learn more about the opportunity. Find out more about what it means to be a PD and register your interest to be the first to receive updates on the recruitment process: link.aria.org.uk/pdc3-x

New opportunity at 23andMe Research Institute! We're looking for a new team member to help us build and deliver clinically useful risk prediction models that can be deployed to consumers and clinicians. 23andme.wd5.myworkdayjobs.com/en-US/23/detai…

Thanks Mitch Leslie @ScienceMagazine for reporting on the @ARPA_H PROSPR program. science.org/content/articl…

R2T is gathering pace!

A much needed effort that @Danbelsky and I have now been funded for to support the FAST initiative ($8 million over 18 months): lnkd.in/eUSU9iqP The goal of this is to provide a set of biomarkers that will tell a person if a geromedicine is having an effect on their aging. It will be very useful for upcoming clinical trials testing geromedicines and also supported by ARPA-H. Read more here: lnkd.in/e_3Hqixv

At NIH, we’re accelerating the future of medical research, advancing innovation and repurposing existing drugs to deliver new treatments faster for the American people🔬🇺🇸

I think, you and I are aligned on the approach, my point is that we dont have the n of 1 positive control, and im not sure there is such a thing. We need to build a new infrastructure, a US biobank with emphasis on longitudinal collection for RWD. Happy to chat in more detail about building.

@BrackLab @bryan_johnson why low n? I think you can do home blood draws and make it pretty cheap. Bryan would agree with that too -- he's just been doing n of 1 b/c he's been willing to pay for it. But no reason can't make it cheap now.

Bingo. Constant molecular monitoring is going to be a huge unlock for health, wellness, and longevity. @bryan_johnson has this right 100%.

Thanks for enganging @jrkelly. Agree with you that constant molecular monitoring -longitudinal measures, is going to be a huge unlock, and when combined with long term health outcomes, but we need to build that data layer out. In line with your passion for lab automation, noise and low n is going to limit interpretations. Bryans focus on his own n-of-1 as a standard of which to map against, with interventions of somewhat unknown utility and to monopolize, is why it’s wrong. But happy to chat about automation of the n of 1 for longevity anytime. We are all living our own adaptive clinical trial.😉

hit me! what don't you like? my general theory is we should be doing as frequent as possible measurement of tons of biomarkers in at least blood. Oura ring but for molecular measurement. Then can do various interventions and see what works -- also likely to get early detection signals of various diseases over time if lots of people start doing this. Easy way to get started IMO is frequent blood collection sent to central labs for broad metabolomics, proteomics, etc.

Nicolas's review highlights the design variables that determine whether a trial produces actionable evidence or noise: population enrichment, dose and schedule, endpoint construction, and confirming the drug is engaging its target. Joan Mannick and Adam Salmon flagged the same gap to Nicolas independently: baseline mTORC1 activation varies enormously between individuals, and there's no reliable way to confirm engagement in a given person. Endpoint selection for longevity is already hard, and this challenge touches on the three other variables. But things are happening, with multiple trials exploring designs and endpoints (several funded by @NornGroup @impetusgrants): VIBRANT-I is a randomized trial at Columbia testing whether weekly low-dose rapamycin can slow ovarian aging in women in their thirties. It hasn’t fully read out but showing early separation in ovarian reserve. A larger followup, VIBRANT-II, is already being set up. RAPID, Jonathan An's clinical trial at the University of Washington, is testing rapamycin in adults over fifty with periodontal disease, with biological aging biomarkers and microbiome sequencing built into the protocol alongside the clinical endpoints. Kaeberlein et al's survey of 333 off-label users provided the human safety data that made the controlled trial possible. ERAP, a Phase IIa trial out of the Karolinska Institute, tested weekly rapamycin in fourteen early-stage Alzheimer's patients over six months, with cerebral glucose uptake as the primary endpoint. This derisked the design for rapamycin trials in Alzheimer's, with primary imaging endpoints steady or even increased in exploratory regions compared to natural history disease progression. @LammingLab's RAP-PROTECT trial at Wisconsin recruited fifty people who already take rapamycin off-label, drew their blood at home using mobile phlebotomy, and ran it through metabolomic and lipidomic profiling to see which aging biomarkers actually respond to mTORC1 inhibition. Results expected this year. And elsewhere: Marmoset survival data from a 10-year, 66-animal study is incoming. And @BrackLab @ARPA_H just committed up to $144M across seven longevity teams, two of which are mTOR inhibitors. Trial design and infrastructure might finally be catching up to the science...